MyeloPro

MyeloPro is a Vienna-based biopharmaceutical company specializing in the development of innovative therapeutics for myeloproliferative neoplasms (MPNs). Founded by pioneers in MPN research, the company focuses on targeting specific genetic drivers such as mutated calreticulin (CALR) and JAK2. Its lead program, a T-cell redirecting bispecific antibody targeting mutated CALR, is currently in Phase 1 clinical trials in collaboration with Janssen. MyeloPro's pipeline also includes preclinical biological candidates and discovery-stage small molecules and vaccines aimed at eradicating malignant clones in blood cancers. The company leverages deep expertise in hematology to address high medical needs in rare orphan blood malignancies.